title: Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.
abstract: Nonacog alfa is a recombinant factor IX (FIX) product indicated for treatment and prevention of bleeding episodes in patients with haemophilia B. This posthoc analysis evaluated the safety of nonacog alfa in key clinical studies across 15 years. Data were pooled from six prospective studies that utilized on-demand, prophylactic and preventive nonacog alfa regimens: three open-label, nonrandomized studies that assessed efficacy and safety; a bioequivalence study of original and reformulated nonacog alfa; an open-label, randomized study that compared on-demand and prophylactic treatment; and a noninterventional observational registry study that evaluated safety. Safety assessments included adverse events, serious adverse events (SAEs) and events of special interest. In total, 412 patients received nonacog alfa treatment. Adverse events occurred in 220 patients (53.4%), the most common being pyrexia (n = 63), nasopharyngitis (n = 53) and cough (n = 52). Forty-eight patients (11.7%) experienced treatment-related adverse events; the most common were hypersensitivity (n = 6), urticaria (n = 6), FIX inhibition (n = 5) and pyrexia (n = 4). Seventy-four patients (18.0%) developed SAEs. Thirty-seven events of special interest occurred in 31 (7.5%) patients. Events of special interest included allergic-type manifestations (n = 15), inhibitor development (n = 5), lack of effect (n = 8), red blood cell agglutination in tubing or syringe (n = 7), and thrombogenicity (n = 2). Six patients (1.5%) withdrew due to seven adverse events: hypersensitivity (n = 3), drug eruption, pruritic rash, urticaria and decreased therapeutic response (n = 1 each). Four patients died during the study; no deaths were related to study medication. This pooled safety analysis in haemophilia B patients confirmed the safety of nonacog alfa across various patient populations.
authors.affiliation: aPfizer Inc, Collegeville, Pennsylvania bPfizer Inc, Groton, Connecticut, USA.
authors.forename: Pablo
authors.initials: P
authors.lastname: Rendo
authors.forename: Lynne
authors.initials: L
authors.lastname: Smith
authors.forename: Hsiao-Yu
authors.initials: HY
authors.lastname: Lee
authors.forename: Frank
authors.initials: F
authors.lastname: Shafer
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003029:Coagulants / Q000008:administration & dosage* / Q000009:adverse effects; D003371:Cough / Q000209:etiology / Q000503:physiopathology; D004342:Drug Hypersensitivity / Q000209:etiology / Q000503:physiopathology; D005164:Factor IX / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005334:Fever / Q000209:etiology / Q000503:physiopathology; D002836:Hemophilia B / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D009304:Nasopharyngitis / Q000209:etiology / Q000503:physiopathology; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D014581:Urticaria / Q000209:etiology / Q000503:physiopathology
chemical_list: D003029:Coagulants; D011994:Recombinant Proteins; D005164:Factor IX